Replies to post #130961 on Biotech Values

[biomaven0]

safety and long term data are more important to get market share

I completely agree. It's still much too early to say whether or not pona will ever get any share of 1st line. Its market for the mid-term is going to be 3rd-line and some 2nd-line.

Peter

[rkrw]

fwiw. Sprycel+Tasigna are now annualizing at > $1.8b/year even though Gleevec is still dominating front line..